Hapworth Research Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$16,140	1
2023	Research	$72,551	30
2022	Research	$410,270	39
2021	Research	$173,598	27
2020	Research	$245,359	37
2019	Research	$330,164	23

Breakdown

Who paid Research payments · program years 2019–2025

LivaNova USA, Inc. $668,956 101 payments
Genentech, Inc. $435,447 26 payments
Sage Therapeutics, Inc. $92,136 14 payments
Janssen Research & Development, LLC $41,178 8 payments
Biohaven Pharmaceutical Holding Company Ltd. $7,902 5 payments
Biohaven Pharmaceuticals, Inc. $2,465 3 payments

Studies the money was for Research payments · program years 2019–2025

Phase III Study of Balovaptan in Adults With Asd $435,447 26 payments
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $295,640 56 payments
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $249,809 36 payments
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes $118,329 4 payments
217-Mdd-303 $61,996 5 payments
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $30,140 9 payments
A Randomized, Multicenter, Crossover Study to Assess the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Subjects With Major Depressive Disorder $25,038 7 payments
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $16,140 1 payment
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $6,667 7 payments
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) $5,178 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.